StatLab Medical Products Sold to Leica Biosystems in Strategic Exit
Event summary
- Audax Private Equity and Linden Capital Partners agreed to sell StatLab Medical Products to Leica Biosystems, an operating company of Danaher Corporation.
- StatLab expanded from a U.S.-focused business into a global manufacturer during Audax and Linden's ownership, completing nine strategic acquisitions.
- The transaction is subject to customary closing conditions and was announced on July 14, 2026.
The big picture
This deal marks a strategic exit for Audax and Linden, who transformed StatLab from a regional player into a global manufacturer through acquisitions and operational investments. The sale to Leica Biosystems aligns with Danaher's strategy of consolidating specialized diagnostics providers, reflecting broader industry trends toward vertical integration in healthcare.
What we're watching
- Integration Strategy
- How Leica Biosystems will integrate StatLab's manufacturing capabilities and customer base into its existing operations.
- Market Expansion
- Whether Danaher can leverage StatLab's European presence to strengthen its global diagnostics portfolio.
- Execution Risk
- The pace at which StatLab can maintain growth momentum under new ownership.
Related topics